• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Zymeworks Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Zymeworks to Transfer Stock Listing to Nasdaq
December 05, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
November 29, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Participation in Upcoming Investor Conference
November 22, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
November 21, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 08, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
October 20, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
October 19, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks to Host Third Quarter Results Conference Call
October 18, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Completes Plan to Become Delaware Corporation
October 13, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Results of Special Meeting
October 07, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
October 03, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
September 26, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
September 16, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
September 12, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
September 08, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
September 04, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 04, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
August 01, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
July 25, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
July 22, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks to Host Second Quarter Results Conference Call
July 21, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Plan to Become a Delaware Corporation
July 15, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
June 27, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
June 10, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Participation in Upcoming Investor Conference
May 27, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
May 26, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
May 20, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 04, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
May 02, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
April 28, 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap